• Skip to main content
  • Skip to footer
cnb1439_3rs-project_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Organ-on-a-Chip Resources

Resource type

Area of interest

Blogs

Resource image

Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies

Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins, and formulation design.

Brochures & Flyers

Resource image

PhysioMimix Bioavailability assay kit: Human 18 brochure

Modernize your workflow with the only in vitro bioavailability assessment tool on the market. Elevate your workflow with our all-in-one Bioavailability assay kit containing everything you need to recreate our human in vitro Gut/Liver-on-a-chip model and Bioavailability assay in your laboratory.

Videos and animations

Resource image

PhysioMimix® bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling

Discover the PhysioMimix® Bioavailability assay kit: Human 18, the only in vitro tool for profiling human bioavailability. This Organ-on-a-chip solution bridges the gap between in vitro and in vivo studies, enhancing preclinical ADME testing for CROs, pharma, and biotech. Explore how it streamlines lead optimization and improves drug development accuracy.

Articles

Resource image

Addressing the challenges of developing new modality drugs

Discover how new modality drugs are revolutionizing medicine by targeting complex diseases with cutting-edge therapies. Learn about the challenges, innovative solutions, and the role of AI and Organ-on-a-chip (OOC) technology in new modality drug development. Expert insights.

Videos and animations

Resource image

Validating a human dual-organ MPS for better drug (ADME) studies

In this video from Technology Networks’ Science Spotlight, Dr. Yassen Abbas, Lead scientist at CN Bio, discusses his research on ADME and how microphysiological system (MPS), also known as Organ-on-a-chip (OOC) technology can be used to evaluate the body’s effect on drugs.

Webinars

Resource image

A Gut/Liver microphysiological system for profiling human oral bioavailability

Webinar Series 7 Episode 4

Explore how the innovative Gut/Liver microphysiological system (MPS) enhances in vitro ADME profiling by linking primary human intestinal and liver cells to predict human drug bioavailability more accurately. This webinar demonstrates improved predictive capacity for complex drug behaviors, advancing drug discovery and safety assessment.

Blogs

Resource image

Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?

Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and permeability. However, as with any model system, Caco-2 cells have their own set of limitations. This raises important questions: Do their limitations undermine their gold-standard status? Is it time to improve estimations with more physiologically relevant approaches? What new approaches are available, and most importantly, do their benefits sufficiently outweigh the effort required to adopt a new approach?

Blogs

Resource image

6 Challenges in ADME Drug Development

Explore the current challenges in profiling preclinical human ADME through key publications. Can advances in the human relevance of preclinical models improve estimations for safer and more efficient drug development?

Posters

Resource image

Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS

Improve in vitro to in vivo data translation for drug safety and efficacy with our fluidically-linked dual-organ MPS (microphysiological system); combining two well-characterized human Gut/Liver MPS – the RepliGut® Jejunum and PhysioMimix® Liver MPS, in an interconnected model suitable for enhanced bioavailability profiling.

Blogs

Resource image

How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials

This blog explores a world where novel multi-organ in vitro models, tiny replicas of the human intestine and liver, provide the key to unlocking a deeper understanding of how we Absorb, Distribute and Metabolize drugs.

Read more to discover why accurately estimating human ADME remains a challenge and a potential solution that enables greater confidence in lead candidates and a reduced risk of identifying poor oral bioavailability during first in human studies.

Application notes

Resource image

Connecting the gut and liver

A human-relevant dual-organ microphysiological system connecting the gut and liver for preclinical profiling of oral bioavailability

Discover a new PhysioMimix® microphysiological system (MPS) that connects primary human RepliGut® and liver models to overcome the limitations of preclinical drug ADME profiling. Download the Application Note to explore the MPS’ evaluation of Temocapril and Midazolam, demonstrating its ability to provide more accurate predictions and change the risk calculus for safer and more efficient drug development.

Posters

Resource image

Connecting the human intestine and liver

A primary jejunum and primary hepatocyte multi-organ MPS for more predictive studies of human drug ADME and oral bioavailability

Traditional immortalized intestinal cell lines and suspension hepatocytes have absent or low levels of metabolic enzyme expression, and thus fail to predict first pass human metabolism and oral bioavailability.

Efforts to improve the in vitro to in vivo translation of drug efficacy and safety data has led to the emergence of more human relevant microphysiological systems (MPS) that consist of multiple, fluidically linked organs1.

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
Cyber Essentials Logo